10:15 AM EST - Aeterna Zentaris Inc. : Announced that results from pre-clinical studies of Aeterna’s AIM Biologicals for the potential treatment of Parkinson’s Disease were accepted for presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists, to be held May 6-10 in Portland, Oregon. Aeterna Zentaris Inc.
shares T.AEZS are trading down $0.01 at $0.38.
